Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori

Pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI

Tadashi Ohara, Tetsuo Morishita, Hidekazu Suzuki, Tatsuhiro Masaoka, Hiromasa Ishii

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background/Aims: Problems after Helicobacter pylori (Hp) eradication therapy include recurrence of Hp-negative peptic ulcers. We investigated the pathophysiological characteristics of Hp-negative recurrent ulcer scars, and performed proton pump inhibitor (PPI) maintenance therapy as a new therapy for prevention of recurrence in patients with Hp-negative recurrence after Hp eradication and investigated its usefulness. Methodology: The subjects were 21 patients with Hp-negative recurrent peptic ulcers after Hp eradication (gastric ulcer: 19, duodenal ulcer: 2) and 25 patients with non-recurrent ulcers (gastric ulcer: 20, duodenal ulcer: 5). The mucosa from the ulcer scar lesion was endoscopically obtained from patients, and HE staining, CD68 immunohistochemical staining, and investigation of the mucosal expression levels of TNF-α and IFN-γ were performed by ELISA. Patients with recurrence after eradication were divided into two groups at the time of ulcer scar after the first treatment, and received maintenance therapy: the intermittent treatment group that received lansoprazole (LPZ), 30mg/day, on two days on weekends (gastric ulcer: 9, duodenal ulcer: 1) and the ranitidine (RAN) 150mg/day daily treatment group (gastric ulcer: 8, duodenal ulcer: 1). Results: Infiltration of CD68-positive inflammatory cells was observed in the lamina propria mucosae over the epithelial layer in ulcer scars of the Hp-negative recurrent ulcer group compared with the non-recurrent ulcer group, and TNF-α and IFN-γ significantly increased (27.22±6.23pg/mg, 52.12±5.41pg/ mg vs. 4.23±2.14pg/mg, 7.11±3.06pg/mg, P<0.001). In the RAN maintenance therapy group, the ulcer recurred within 10 months in all patients, while the ulcer recurred in only one patient in the intermittent LPZ treatment group. Conclusions: These results suggested that the pathophysiological characteristic of Hp-negative recurrent ulcer scar lesions after eradication was infiltration of inflammatory cells, mainly monocytes/ macrophages, in the lamina propria mucosae over the epithelial layer, and this may be a key factor in ulcer recurrence. Furthermore, intermittent PPI therapy using LPZ may be a useful maintenance therapy for prevention of recurrence in these cases.

Original languageEnglish
Pages (from-to)338-342
Number of pages5
JournalHepato-Gastroenterology
Volume51
Issue number56
Publication statusPublished - 2004 Mar

Fingerprint

Proton Pump Inhibitors
Pylorus
Peptic Ulcer
Ulcer
Cicatrix
Helicobacter pylori
Acids
Stomach Ulcer
Duodenal Ulcer
Lansoprazole
Mucous Membrane
Recurrence
Therapeutics
Ranitidine
Staining and Labeling
Group Psychotherapy
Monocytes
Enzyme-Linked Immunosorbent Assay
Macrophages

Keywords

  • H. pylori eradication
  • H. pylori-negative recurrent ulcer
  • Intermittent PPI therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{85c92d75fdc94468888a54252867f134,
title = "Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: Pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI",
abstract = "Background/Aims: Problems after Helicobacter pylori (Hp) eradication therapy include recurrence of Hp-negative peptic ulcers. We investigated the pathophysiological characteristics of Hp-negative recurrent ulcer scars, and performed proton pump inhibitor (PPI) maintenance therapy as a new therapy for prevention of recurrence in patients with Hp-negative recurrence after Hp eradication and investigated its usefulness. Methodology: The subjects were 21 patients with Hp-negative recurrent peptic ulcers after Hp eradication (gastric ulcer: 19, duodenal ulcer: 2) and 25 patients with non-recurrent ulcers (gastric ulcer: 20, duodenal ulcer: 5). The mucosa from the ulcer scar lesion was endoscopically obtained from patients, and HE staining, CD68 immunohistochemical staining, and investigation of the mucosal expression levels of TNF-α and IFN-γ were performed by ELISA. Patients with recurrence after eradication were divided into two groups at the time of ulcer scar after the first treatment, and received maintenance therapy: the intermittent treatment group that received lansoprazole (LPZ), 30mg/day, on two days on weekends (gastric ulcer: 9, duodenal ulcer: 1) and the ranitidine (RAN) 150mg/day daily treatment group (gastric ulcer: 8, duodenal ulcer: 1). Results: Infiltration of CD68-positive inflammatory cells was observed in the lamina propria mucosae over the epithelial layer in ulcer scars of the Hp-negative recurrent ulcer group compared with the non-recurrent ulcer group, and TNF-α and IFN-γ significantly increased (27.22±6.23pg/mg, 52.12±5.41pg/ mg vs. 4.23±2.14pg/mg, 7.11±3.06pg/mg, P<0.001). In the RAN maintenance therapy group, the ulcer recurred within 10 months in all patients, while the ulcer recurred in only one patient in the intermittent LPZ treatment group. Conclusions: These results suggested that the pathophysiological characteristic of Hp-negative recurrent ulcer scar lesions after eradication was infiltration of inflammatory cells, mainly monocytes/ macrophages, in the lamina propria mucosae over the epithelial layer, and this may be a key factor in ulcer recurrence. Furthermore, intermittent PPI therapy using LPZ may be a useful maintenance therapy for prevention of recurrence in these cases.",
keywords = "H. pylori eradication, H. pylori-negative recurrent ulcer, Intermittent PPI therapy",
author = "Tadashi Ohara and Tetsuo Morishita and Hidekazu Suzuki and Tatsuhiro Masaoka and Hiromasa Ishii",
year = "2004",
month = "3",
language = "English",
volume = "51",
pages = "338--342",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "56",

}

TY - JOUR

T1 - Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori

T2 - Pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI

AU - Ohara, Tadashi

AU - Morishita, Tetsuo

AU - Suzuki, Hidekazu

AU - Masaoka, Tatsuhiro

AU - Ishii, Hiromasa

PY - 2004/3

Y1 - 2004/3

N2 - Background/Aims: Problems after Helicobacter pylori (Hp) eradication therapy include recurrence of Hp-negative peptic ulcers. We investigated the pathophysiological characteristics of Hp-negative recurrent ulcer scars, and performed proton pump inhibitor (PPI) maintenance therapy as a new therapy for prevention of recurrence in patients with Hp-negative recurrence after Hp eradication and investigated its usefulness. Methodology: The subjects were 21 patients with Hp-negative recurrent peptic ulcers after Hp eradication (gastric ulcer: 19, duodenal ulcer: 2) and 25 patients with non-recurrent ulcers (gastric ulcer: 20, duodenal ulcer: 5). The mucosa from the ulcer scar lesion was endoscopically obtained from patients, and HE staining, CD68 immunohistochemical staining, and investigation of the mucosal expression levels of TNF-α and IFN-γ were performed by ELISA. Patients with recurrence after eradication were divided into two groups at the time of ulcer scar after the first treatment, and received maintenance therapy: the intermittent treatment group that received lansoprazole (LPZ), 30mg/day, on two days on weekends (gastric ulcer: 9, duodenal ulcer: 1) and the ranitidine (RAN) 150mg/day daily treatment group (gastric ulcer: 8, duodenal ulcer: 1). Results: Infiltration of CD68-positive inflammatory cells was observed in the lamina propria mucosae over the epithelial layer in ulcer scars of the Hp-negative recurrent ulcer group compared with the non-recurrent ulcer group, and TNF-α and IFN-γ significantly increased (27.22±6.23pg/mg, 52.12±5.41pg/ mg vs. 4.23±2.14pg/mg, 7.11±3.06pg/mg, P<0.001). In the RAN maintenance therapy group, the ulcer recurred within 10 months in all patients, while the ulcer recurred in only one patient in the intermittent LPZ treatment group. Conclusions: These results suggested that the pathophysiological characteristic of Hp-negative recurrent ulcer scar lesions after eradication was infiltration of inflammatory cells, mainly monocytes/ macrophages, in the lamina propria mucosae over the epithelial layer, and this may be a key factor in ulcer recurrence. Furthermore, intermittent PPI therapy using LPZ may be a useful maintenance therapy for prevention of recurrence in these cases.

AB - Background/Aims: Problems after Helicobacter pylori (Hp) eradication therapy include recurrence of Hp-negative peptic ulcers. We investigated the pathophysiological characteristics of Hp-negative recurrent ulcer scars, and performed proton pump inhibitor (PPI) maintenance therapy as a new therapy for prevention of recurrence in patients with Hp-negative recurrence after Hp eradication and investigated its usefulness. Methodology: The subjects were 21 patients with Hp-negative recurrent peptic ulcers after Hp eradication (gastric ulcer: 19, duodenal ulcer: 2) and 25 patients with non-recurrent ulcers (gastric ulcer: 20, duodenal ulcer: 5). The mucosa from the ulcer scar lesion was endoscopically obtained from patients, and HE staining, CD68 immunohistochemical staining, and investigation of the mucosal expression levels of TNF-α and IFN-γ were performed by ELISA. Patients with recurrence after eradication were divided into two groups at the time of ulcer scar after the first treatment, and received maintenance therapy: the intermittent treatment group that received lansoprazole (LPZ), 30mg/day, on two days on weekends (gastric ulcer: 9, duodenal ulcer: 1) and the ranitidine (RAN) 150mg/day daily treatment group (gastric ulcer: 8, duodenal ulcer: 1). Results: Infiltration of CD68-positive inflammatory cells was observed in the lamina propria mucosae over the epithelial layer in ulcer scars of the Hp-negative recurrent ulcer group compared with the non-recurrent ulcer group, and TNF-α and IFN-γ significantly increased (27.22±6.23pg/mg, 52.12±5.41pg/ mg vs. 4.23±2.14pg/mg, 7.11±3.06pg/mg, P<0.001). In the RAN maintenance therapy group, the ulcer recurred within 10 months in all patients, while the ulcer recurred in only one patient in the intermittent LPZ treatment group. Conclusions: These results suggested that the pathophysiological characteristic of Hp-negative recurrent ulcer scar lesions after eradication was infiltration of inflammatory cells, mainly monocytes/ macrophages, in the lamina propria mucosae over the epithelial layer, and this may be a key factor in ulcer recurrence. Furthermore, intermittent PPI therapy using LPZ may be a useful maintenance therapy for prevention of recurrence in these cases.

KW - H. pylori eradication

KW - H. pylori-negative recurrent ulcer

KW - Intermittent PPI therapy

UR - http://www.scopus.com/inward/record.url?scp=1842535526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842535526&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 338

EP - 342

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 56

ER -